The RNA Binding Protein HuR Differentially Regulates Unique Subsets of MRNAs in Estrogen Receptor Negative and Estrogen Receptor Positive Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Apr 8

PMID 20370918

Citations 42

Authors

Robert Calaluce

Matthew M Gubin

J Wade Davis

Joseph D Magee

Jing Chen

Yuki Kuwano

Myriam Gorospe

Ulus Atasoy

Affiliations

Soon will be listed here.

Abstract

Background: The discordance between steady-state levels of mRNAs and protein has been attributed to posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA targets owing to significant posttranscriptional gene regulation by RNA binding proteins (RBPs).

Methods: The ribonomic approach, utilizing RNA immunoprecipitation hybridized to microarray (RIP-Chip), provides global identification of putative endogenous mRNA targets of different RBPs. HuR is an RBP that binds to the AU-rich elements (ARE) of labile mRNAs, such as proto-oncogenes, facilitating their translation into protein. HuR has been shown to play a role in cancer progression and elevated levels of cytoplasmic HuR directly correlate with increased invasiveness and poor prognosis for many cancers, including those of the breast. HuR has been described to control genes in several of the acquired capabilities of cancer and has been hypothesized to be a tumor-maintenance gene, allowing for cancers to proliferate once they are established.

Results: We used HuR RIP-Chip as a comprehensive and systematic method to survey breast cancer target genes in both MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen receptor negative, ER-) breast cancer cell lines. We identified unique subsets of HuR-associated mRNAs found individually or in both cell types. Two novel HuR targets, CD9 and CALM2 mRNAs, were identified and validated by quantitative RT-PCR and biotin pull-down analysis.

Conclusion: This is the first report of a side-by-side genome-wide comparison of HuR-associated targets in wild type ER+ and ER- breast cancer. We found distinct, differentially expressed subsets of cancer related genes in ER+ and ER- breast cancer cell lines, and noted that the differential regulation of two cancer-related genes by HuR was contingent upon the cellular environment.

Citing Articles

Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling.

Zhang Q, Yang Z, Hao X, Dandreo L, He L, Zhang Y Cell Biosci. 2023; 13(1):192.

PMID: 37848943 PMC: 10583380. DOI: 10.1186/s13578-023-01137-w.

MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.

Chaudhary S, Appadurai M, Maurya S, Nallasamy P, Marimuthu S, Shah A Breast Cancer Res. 2023; 25(1):25.

PMID: 36918912 PMC: 10012760. DOI: 10.1186/s13058-023-01630-7.

RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer.

Mehta M, Raguraman R, Ramesh R, Munshi A Adv Drug Deliv Rev. 2022; 191:114569.

PMID: 36252617 PMC: 10411638. DOI: 10.1016/j.addr.2022.114569.

The function and regulatory mechanism of RNA-binding proteins in breast cancer and their future clinical treatment prospects.

Lu X, Zhong J, Liu L, Zhang W, Zhao S, Chen L Front Oncol. 2022; 12:929037.

PMID: 36052258 PMC: 9424610. DOI: 10.3389/fonc.2022.929037.

Research progress on RNA-binding proteins in breast cancer.

Zhang W, Liu L, Zhao S, Chen L, Wei Y, Chen W Oncol Lett. 2022; 23(4):121.

PMID: 35261635 PMC: 8867207. DOI: 10.3892/ol.2022.13241.

References

Grigull J, Mnaimneh S, Pootoolal J, Robinson M, Hughes T . Genome-wide analysis of mRNA stability using transcription inhibitors and microarrays reveals posttranscriptional control of ribosome biogenesis factors. Mol Cell Biol. 2004; 24(12):5534-47. PMC: 419893. DOI: 10.1128/MCB.24.12.5534-5547.2004. View

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M . A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 2009; 44(9):889-96. DOI: 10.1007/s00535-009-0081-3. View

Muss H . Targeted therapy for metastatic breast cancer. N Engl J Med. 2006; 355(26):2783-5. DOI: 10.1056/NEJMe068260. View

Galban S, Kuwano Y, Pullmann Jr R, Martindale J, Kim H, Lal A . RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2007; 28(1):93-107. PMC: 2223304. DOI: 10.1128/MCB.00973-07. View

Atasoy U, Curry S, Lopez de Silanes I, Shyu A, Casolaro V, Gorospe M . Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR. J Immunol. 2003; 171(8):4369-78. DOI: 10.4049/jimmunol.171.8.4369. View

Tran H, Maurer F, Nagamine Y . Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003; 23(20):7177-88. PMC: 230330. DOI: 10.1128/MCB.23.20.7177-7188.2003. View

Fan X, Steitz J . Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 1998; 17(12):3448-60. PMC: 1170681. DOI: 10.1093/emboj/17.12.3448. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

10.

Berchtold M, EGLI R, Rhyner J, Hameister H, Strehler E . Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3. Genomics. 1993; 16(2):461-5. DOI: 10.1006/geno.1993.1211. View

11.

Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale J, Gorospe M . Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004; 23(15):3092-102. PMC: 514922. DOI: 10.1038/sj.emboj.7600305. View

12.

Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomaki K, Blomqvist C . Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007; 13(23):6959-63. DOI: 10.1158/1078-0432.CCR-07-1432. View

13.

Meisner N, Hackermuller J, Uhl V, Aszodi A, Jaritz M, Auer M . mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem. 2004; 5(10):1432-47. DOI: 10.1002/cbic.200400219. View

14.

Khabar K, Bakheet T, Williams B . AU-rich transient response transcripts in the human genome: expressed sequence tag clustering and gene discovery approach. Genomics. 2005; 85(2):165-75. DOI: 10.1016/j.ygeno.2004.10.004. View

15.

Nabors L, Gillespie G, Harkins L, King P . HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 2001; 61(5):2154-61. View

16.

Hieronymus H, Silver P . Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. Nat Genet. 2003; 33(2):155-61. DOI: 10.1038/ng1080. View

17.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

18.

Suswam E, Nabors L, Huang Y, Yang X, King P . IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2004; 113(6):911-9. DOI: 10.1002/ijc.20675. View

19.

Levy A . Hypoxic regulation of VEGF mRNA stability by RNA-binding proteins. Trends Cardiovasc Med. 2004; 8(6):246-50. DOI: 10.1016/s1050-1738(98)00020-6. View

20.

Mischel P, Cloughesy T, Nelson S . DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004; 5(10):782-92. DOI: 10.1038/nrn1518. View